文献速递慢性肾脏病水电解质与酸碱

碳酸镧、醋酸钙与限磷饮食对非透析CKD患者的影响:一项随机对照试验

Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial.
PubMed 文献 · Kidney Int Rep · 2018-03-23

本研究为随机对照平行设计试验,纳入120例eGFR 15-59 ml/min/1.73 m²且磷代谢异常的CKD患者,随机接受碳酸镧、醋酸钙或饮食干预1年。共同主要结局为12个月时生化及血管参数较基线的变化,所有分析为意向性治疗。结果显示仅bALP和FGF23有显著变化,三组间除PTH外其余结局变化相似。

要点

  • 限磷饮食或两种磷结合剂治疗1年可降低bALP,提示骨转换改善。
  • 除PTH外,碳酸镧、醋酸钙与饮食干预对生化及血管参数的影响无显著差异。
  • 醋酸钙对PTH的抑制效果优于其他两种干预措施。

核心结论

  • 为期1年的限磷饮食或磷结合剂干预可降低bALP,提示骨转换改善,但未显著改善其他生化或血管参数。

研究设计与样本

  • 随机对照平行设计临床试验,纳入120例eGFR 15-59 ml/min/1.73 m²且磷代谢异常的CKD患者,随机分为碳酸镧、醋酸钙或饮食干预组,随访1年,意向性治疗分析。

主要发现

  • 12个月时仅bALP(中位数13.8 vs 15.8,P < .001)和FGF23(132 vs 133,P = .002)较基线有显著变化。
  • 三组间所有结局变化相似,但醋酸钙对PTH的抑制更有效(P < .001)。
  • 107例(89%)患者完成12个月随访。

关键数值与推荐

  • 入组标准:eGFR 15-59 ml/min/1.73 m²,血清磷>4.6 mg/dl,或PTH>70 pg/ml,或TRP<80%。
  • 共同主要结局为12个月时生化参数(血清磷、TRP、PTH、钙、bALP、FGF23)和血管参数(冠状动脉钙化评分、脉搏波速度、内皮功能障碍)较基线的变化。

临床怎么用

  • 对于CKD 3/4期伴磷代谢异常患者,限磷饮食或磷结合剂可能改善骨转换指标,但未显示血管参数获益。
  • 醋酸钙在抑制PTH方面可能更具优势,但需结合患者具体情况选择。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小(120例),随访时间仅1年。
  • 未报告硬终点(如心血管事件、死亡)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Abnormal phosphorus homeostasis develops early in chronic kidney disease (CKD). It is unclear if its correction results in improved clinical outcomes in non-dialysis dependent CKD. METHODS: We conducted a randomized controlled, parallel design clinical trial in 120 patients with estimated glomerular filtration rate 15 to 59 ml/min per 1.73 m2 and abnormal phosphorus homeostasis (serum phosphorus >4.6 mg/dl, parathyroid hormone [PTH] >70 pg/ml or tubular reabsorption of phosphorus [TRP] <80%). Patients were randomized to open-label lanthanum carbonate versus calcium acetate versus dietary intervention over 1 year. The co-primary outcomes were month 12 (vs. baseline) biochemical (serum phosphorus, TRP, PTH, calcium, bone-specific alkaline phosphatase [bALP], and fibroblast growth factor 23 [FGF23]) and vascular parameters (coronary artery calcium score, pulse wave velocity, and endothelial dysfunction) in all patients. Secondary outcomes were between-treatment differences in change for each parameter between month 12 and baseline. All analyses were intention to treat. RESULTS: Baseline characteristics were similar in the 3 groups. A total of 107 patients (89%) completed 12 months of follow-up. Differences were not significant at month 12 (vs. baseline) for any of the outcomes except bALP (median [25th, 75th] percentile at month 12 versus baseline: 13.8 [10.6, 17.6] vs. 15.8 [12.1, 21.1], P < .001) and FGF23 (132 [99, 216] vs. 133 [86, 189], P = .002). Changes for all outcomes were similar in the 3 arms except for PTH, which was suppressed more effectively by calcium acetate (P < .001). CONCLUSION: A 1-year intervention to limit phosphorus absorption using dietary restriction or 2 different phosphorus binders resulted in decreased bALP suggesting improved bone turnover, but no other significant changes in biochemical or vascular parameters in patients with CKD stage 3/4. (ClinicalTrials.gov: NCT01357317).

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kovesdy CP, Lu JL, Wall BM, et al. Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial. Kidney Int Rep. 2018. PMID: 29989014. doi:10.1016/j.ekir.2018.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。